Involvement of endogenous leukotriene B4 and platelet-activating factor in polymorphonuclear leucocyte recruitment to dermal inflammatory sites in rats.
A critical role for leukotriene B(4) (LTB(4)) and/or platelet-activating factor (PAF) in regulating polymorphonuclear cell (PMN) trafficking to inflammatory sites has been reported in a number of experimental inflammatory models. In vitro, newly synthesized LTB(4) and PAF were shown to act in an autocrine/paracrine or intracrine fashion to enhance intracellular arachidonic acid availability and leukotriene biosynthesis. This suggested potentially cooperative effects of these lipid mediators in regulating PMN extravasation. The present study aimed to elucidate whether endogenous LTB(4) and PAF may both act to regulate plasma extravasation and PMN trafficking to inflammatory sites in experimental inflammation. With this aim, we have used selective and potent PAF and LTB(4) receptor antagonist pretreatments in dermal and pulmonary inflammation models in rats. Our results show additive inhibitory effects of dual LTB(4) and PAF receptor blockade in either PAF- or LTB(4)-elicited cutaneous PMN accumulation compared to single-drug administration. Furthermore, the combined administration of the drugs inhibited the PMN accumulation induced by the chemically unrelated soluble agonists tumour necrosis factor-alpha and C5a. Finally, in a model of pulmonary inflammation induced by the intravenous injection of Sephadex beads, lung neutrophilia was reduced by 63% following the administration of LTB(4) and PAF antagonists, in contrast with the lack of effect of single drug administration. Our results strongly support a role of both endogenous LTB(4) and PAF in regulating PMN trafficking to inflammatory sites in various experimental conditions.
Bélanger
Caroline
C
Faculty of Pharmacy, Université de Montréal, Québec, Canada.
Elimam
Hanan
H
Lefebvre
Julie
J
Borgeat
Pierre
P
Marleau
Sylvie
S
D000818:Animals; D001578:Benzopyrans / Q000494:pharmacology; D002264:Carboxylic Acids / Q000494:pharmacology; D003872:Dermatitis / Q000276:immunology*; D004095:Dihydropyridines / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D007975:Leukotriene B4 / Q000276:immunology*; D008297:Male; D020556:Neutrophil Infiltration / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology; D010972:Platelet Activating Factor / Q000276:immunology*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000276:immunology; D011014:Pneumonia / Q000276:immunology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors / Q000276:immunology; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors / Q000276:immunology; D012867:Skin / Q000276:immunology; D013844:Thiazoles / Q000494:pharmacology
D001578:Benzopyrans; D002264:Carboxylic Acids; D004095:Dihydropyridines; D007093:Imidazoles; D010972:Platelet Activating Factor; D010980:Platelet Membrane Glycoproteins; D043562:Receptors, G-Protein-Coupled; D018102:Receptors, Leukotriene B4; D013844:Thiazoles; C039351:platelet activating factor receptor; C073027:modipafant; D007975:Leukotriene B4; C071317:Foropafant; C089698:CP 105696